Study to Improve Partner Services for STD Prevention
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this study was to examine the efficacy of patient-delivered partner treatment (PDPT) compared to standard partner referral (PR) and booklet enhanced partner referral (BEPR).
| Condition | Intervention | Phase |
|---|---|---|
|
Trichomonas Vaginalis Urethritis |
Behavioral: Patient-delivered partner treatment Behavioral: Booklet-enhanced partner referral |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Prospective Study for Cost-Effectiveness Strategies to Improve Partner Notification: Female Trichomonas and Male Urethritis Studies |
- Index patient report of partner taking medicine at 6-8 weeks
- Index patient re-infection at 6-8 weeks
- Cost effectiveness outcomes
| Estimated Enrollment: | 1500 |
| Study Start Date: | December 2001 |
| Estimated Study Completion Date: | December 2004 |
For partner treatment, index women who were diagnosed with trichomonas vaginalis and index men who were diagnosed with urethritis were randomized to one of three study arms:
Standard partner referral (PR) – index patients were instructed to tell their partners that they need to go to a clinic for STI evaluation and treatment.
Booklet-enhanced partner referral (BEPR) – index patients were given a wallet-sized booklet containing 4 tear-out cards with information for the partner and treatment guidelines for the providers that would see the partners. The partners could then present this card at a clinic to help the clinician better treat them. If index patients had more than 4 partners, they were given additional booklets.
Patient delivered partner treatment (PDPT) – index patients were given packages containing 2 gram metronidazole (for TV patients) or azithromycin 1 gram and cefixime 400 mg (for urethritis patients) for up to 4 identified sex partners. When cefixime was no longer available, ciprofloxacin 500 mg was used. These packages contained written instructions about how to take the medication, warnings about side effects and a nurse’s pager number to call if there were any questions or if the partner encountered any problems. All medications were distributed in containers with childproof caps and the partner’s initial and birthdates were written on the bottle. This was a requirement of the Louisiana State Pharmacy Board. Names were not documented on the index patient's study or medical records.
Eligibility| Ages Eligible for Study: | 16 Years to 44 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Woman attending Family Planning Clinic or men attending STD clinic
- Aged 16-44
- (non-pregnant women) – positive InPouch for trichomonas, or
- (pregnant women) – positive wet mount or InPouch for Trichomonas vaginalis
- (men) a complaint of urethritis which is verified on examination
- Report having >= 1sex partners in past 60 days
- Not presumptively treated for trichomonas (women) or urethritis (men)
- Provide informed consent to be re-contacted by telephone or in person in 14-28 days for a follow-up interview and T vaginalis or CT/GC rescreening
Exclusion Criteria:
Men
- Prisoner
- Has taken cefixime or azithromycin in last two weeks
- Has previously participated in the study
- All female partners are pregnant and did not have male partners Women
- client has taken metronidazole in the last two weeks
- client has been in this study previously
- women who are asymptomatic and in their first trimester of pregnancy
Contacts and Locations| United States, Louisiana | |
| Delgado STD Clinic | |
| New Orleans, Louisiana, United States, 99999 | |
| Orleans Women's Health Clinic | |
| New Orleans, Louisiana, United States, 99999 | |
| Principal Investigator: | Patty Kissinger, PhD | Tulane University School of Public Health and Tropical Medicine |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00207467 History of Changes |
| Other Study ID Numbers: | CDC-NCHSTP-3196, CA# R30/CCR619143-01 |
| Study First Received: | September 13, 2005 |
| Last Updated: | September 13, 2005 |
| Health Authority: | United States: Federal Government |
Keywords provided by Centers for Disease Control and Prevention:
|
patient-delivered partner treatment partner referral sexually transmitted diseases |
Additional relevant MeSH terms:
|
Trichomonas Infections Urethritis Protozoan Infections |
Parasitic Diseases Urethral Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on June 18, 2013